Healthcare / Drug Manufacturers - Specialty & GenericNSE
$162.10
-2.09 (-1.27%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-1.6B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.1B
P/E
33.5x
↑EV/EBITDA
0.3x
↓ROE
3.0%
↑Gross Margin
56.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-19.0%
FCF CAGR
—
FCF margin
-24.6%
FCF / Net income
-3.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.41B · net income $414.2M · FCF $-1.58B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.41B | $6.41B | $5.74B | $17.09B | $12.07B |
| Net Income | $414.2M | $414.2M | $2.50B | $5.39B | $476.0M |
| EBITDA | $31.11B | $31.11B | $2.85B | $7.76B | $2.30B |
| EPS | — | — | 35.21 | 91.18 | -4.28 |
| Gross Margin | 56.0% | 56.0% | 49.9% | 41.7% | 36.5% |
| Operating Margin | 2.3% | 2.3% | -5.5% | 14.2% | 15.0% |
| Net Margin | 6.5% | 6.5% | 43.6% | 31.5% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.27 | 1.26 |
| Current Ratio | 3.80 | 3.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.58B | $-1.58B | $-931.0M | $-2.60B | $1.82B |
| Returns | |||||
| ROE | 3.0% | 3.0% | 21.4% | 66.3% | 7.0% |
| Valuation | |||||
| P/E | 33.49 | 33.49 | 2.44 | 1.41 | — |
| EV/EBITDA | 0.32 | 0.32 | 0.84 | 0.64 | 5.24 |
| P/B | 1.02 | 1.02 | 0.52 | 0.93 | 0.53 |
| Growth & Yield | |||||
| Revenue Growth | 11.7% | 11.7% | -66.4% | 41.6% | — |
| EPS Growth | — | — | -61.4% | 2230.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+94.0%
Start / end P/E
n/dx → n/dx
EPS bridge
35.21 → n/d
Residual
+94.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.